Clinical Trials

Showing trials with last updates posted in 2024.

NCT04913337 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
179 participants

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Study Type:
INTERVENTIONAL
Last Updated:
2024-10-02
Start Date:
2021-06-09
Completion:
2025-02-28
Conditions
  • Mesothelioma
  • Glioblastoma
  • Renal Cell Carcinoma
  • Non Small Cell Lung Cancer
  • Melanoma
  • Pancreatic Ductal Adenocarcinoma
  • Gastric Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • Cholangiocarcinoma
  • Breast Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Endocervical Cancer
  • Colorectal Cancer
  • Esophageal Cancer
Interventions
  • DRUG
No Results Yet
NCT04683939 | TERMINATED | PHASE1/PHASE2
13 participants

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2024-10-02
Start Date:
2022-01-18
Completion:
2023-07-24
Conditions
  • Solid Tumor
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Esophageal Adenocarcinoma
  • Pancreatic Cancer
  • Biliary Tract Cancer
  • Cholangiocarcinoma
  • Metastatic Cancer
Interventions
  • DRUG
NCT03872388 | TERMINATED | PHASE2
6 participants

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Study Type:
INTERVENTIONAL
Last Updated:
2024-10-02
Start Date:
2019-09-23
Completion:
2023-10-19
Conditions
  • Anatomic Stage IIB Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IIIA Breast Cancer AJCC v8
  • Anatomic Stage IIIB Breast Cancer AJCC v8
  • Anatomic Stage IIIC Breast Cancer AJCC v8
  • Estrogen Receptor Negative
  • HER2/Neu Negative
  • Inflammatory Breast Carcinoma
  • Progesterone Receptor Negative
  • Prognostic Stage IIB Breast Cancer AJCC v8
  • Prognostic Stage III Breast Cancer AJCC v8
  • Prognostic Stage IIIA Breast Cancer AJCC v8
  • Prognostic Stage IIIB Breast Cancer AJCC v8
  • Prognostic Stage IIIC Breast Cancer AJCC v8
  • Stage IIB Breast Cancer AJCC v6 and v7
  • Stage III Breast Cancer AJCC v7
  • Stage IIIA Breast Cancer AJCC v7
  • Stage IIIB Breast Cancer AJCC v7
  • Stage IIIC Breast Cancer AJCC v7
  • Triple-Negative Breast Carcinoma
Interventions
  • DRUG
NCT03839771 | ACTIVE_NOT_RECRUITING | PHASE3
968 participants

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Study Type:
INTERVENTIONAL
Last Updated:
2024-10-02
Start Date:
2019-03-01
Completion:
2027-04-17
Conditions
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome With Excess Blasts-2
Interventions
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page